Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials

Objective: To evaluate late (week 40 or 42; hereafter, week 40/42) metabolic outcomes by early glycemic response (